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Abstract: Familial hypercholesterolemia (FH) is an autosomal-dominant inherited disease 
with a prevalence of one in 500 (heterozygous) to one in 1,000,000 (homozygous).   Mutations 
of the low-density lipoprotein (LDL) receptor gene, the apolipoprotein B100 gene, or the 
PCSK9 gene may be responsible for the disease. The resulting LDL hypercholesterolemia 
results in premature atherosclerosis as early as childhood (homozygous FH) or in adulthood 
(heterozygous FH). Current treatment modalities include lifestyle modification, combination 
drug therapy (statin-based), and apheresis. Mipomersen is an antisense oligonucleotide which 
inhibits apolipoprotein B production independent of LDL receptor function and thus works in 
homozygous FH, heterozygous FH, and other forms of hypercholesterolemia. Mipomersen is 
given 200 mg/week subcutaneously. Phase III studies indicate that the LDL cholesterol con-
centration can be reduced by 25%–47%, lipoprotein(a) levels by 20%–40%, and triglyceride 
concentrations by approximately 10%. In general, mipomersen has no effect on high-density 
lipoprotein cholesterol concentrations. Although there is considerable interindividual variability, 
the observed lipid effects are largely independent of age, gender, concomitant statin therapy, 
and underlying dyslipoproteinemia. The most common side effects are injection site reactions 
(70%–100%), flu-like symptoms (29%–46%), and elevated transaminases associated with an 
increased liver fat content (6%–15%). Mipomersen may be an interesting addon drug in patients 
with heterozygous or homozygous FH not reaching treatment goals, either because baseline 
values are very high or because high-dose statins are not tolerated.
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Core  evidence  clinical  impact  summary  for  mipomersen  for  familial 
hypercholesterolemia (FH)
Outcome measure Evidence Implications
Disease-oriented evidence
LDL-cholesterol reduction Substantial In patients with homozygous or 
heterozygous FH LDL-cholesterol reduction 
of 25%–47% on top of maximally tolerated 
drug therapy
Lipoprotein(a) reduction Substantial Approximately 30% lipoprotein(a) reduction; 
Significant reduction of lipoprotein(a), not 
achievable with currently available drugs
Patient-oriented evidence
Injection site reactions Substantial Most patients (70–100%) describe injection 
site reaction
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Familial hypercholesterolemia
Familial hypercholesterolemia (FH) is an inherited disease, 
characterized by an autosomal-dominant mode of inheritance. 
Heterozygous FH has a prevalence of approximately one in 
500 while the prevalence of homozygous FH is approximately 
one in 1,000,000 in Western Europe. The frequency may 
be considerably higher in selected populations with high 
consanguinity.
Mutations of the low-density lipoprotein (LDL) receptor 
gene are the underlying defect in the majority of FH patients, 
but mutations in two other genes can also cause FH, ie, 
mutations in the apolipoprotein B100 gene and mutations 
in the pro-protein convertase subtilisin/kexin type 9 gene. 
The LDL receptor gene is located on   chromosome 19, and 
more than 1000 mutations affecting the function of the 
receptor are described.1 The resulting defects refer to differ-
ent functions, ie, ligand binding, transport, internalization, 
recycling, or total lack or   receptors.1 Several types of LDL 
receptor mutation have been described, including premature 
stop codons, single amino acid substitutions, large rear-
rangements, mutations affecting the promoter region, and 
mutations affecting splicing of premessenger RNA. Clini-
cally, the most severe forms of FH are related to total lack 
of receptors, while receptor-defective mutations usually lead 
to lesser symptoms.
Although it was initially thought that FH is characterized by 
an overproduction of lipoproteins, kinetic studies, and particu-
larly the work of Brown and Goldstein, demonstrated that the 
underlying metabolic defect in FH is the absence of a high 
affinity receptor for uptake of LDL.2,3
Clinical FH can also be the result of ligand-defective 
  apolipoprotein B. In contrast with the many mutations 
described for the LDL receptor, there are only two 
mutations described for defective apolipoprotein B (both 
affecting ARG 3500).4,5 Finally, gain of function mutations 
of PCSK9 may also lead to clinical FH, because PCSK9 
reduces hepatic LDL receptor activity.6 Interestingly, loss of 
function mutations are associated with lower LDL cholesterol 
concentrations and less atherosclerosis.7
FH is characterized by elevated plasma LDL cholesterol 
and apolipoprotein B levels, resulting in a severely increased 
risk for atherosclerosis. In untreated patients, clinical symp-
toms of atherosclerosis typically develop in the fourth or 
fifth decade of life. Other risk factors, such as smoking, 
hypertension, diabetes, and elevated lipoprotein(a) may 
change the clinical course.
Current treatment options
Current guidelines recommend lowering the LDL cholesterol 
concentration by at least 50% of baseline.8 Ideally, a LDL 
cholesterol level ,100 mg/dL should be achieved. Lifestyle 
modification, statins, ezetimibe, bile acid sequestrants, 
nicotinic acid, and fibrates are used to achieve this goal. 
Lifestyle modification aims at lowering LDL cholesterol 
and reducing other risk factors for cardiovascular disease.9 
However, in patients with FH, only a modest reduction of 
LDL cholesterol can be induced, even if the diet contains 
less than 7%   saturated fat and less than 200 mg cholesterol 
per day. Although helpful and generally recommended, 
these means are rarely sufficient to achieve treatment goals. 
Therefore, drug therapy is required in almost all patients.
Statins can safely lower LDL cholesterol levels by 
up to 50%, and there is overwhelming evidence that statins 
reduce cardiovascular morbidity and mortality as well as 
overall mortality.10,11 It has also been shown that the prognosis 
of patients with heterozygous and homozygous FH has been 
dramatically improved since the introduction of statins.12,13 
While patients with heterozygous FH usually respond very 
well to statin treatment, the response rate in homozygous 
FH is usually less predictable. Depending on the underlying 
defect, LDL cholesterol reductions between 0% and 50% 
are observed in such patients. Observational data from large 
cohorts suggest that long-term statin treatment reduces the 
risk of cardiovascular disease considerably.14
However, treatment goals cannot be achieved by statin 
therapy in many patients, or statin therapy is contraindi-
cated or poorly tolerated. Ezetimibe, bile acid sequestrants, 
  nicotinic acid, and fibrates may be used in this situation, either 
(Continued)
Outcome measure Evidence Implications
Flu-like symptoms Moderate Approximately 30% of patients describe 
flu-like symptoms (not significantly different 
from placebo)
Elevated LFTs Moderate 6%–15% of patients have elevated LFTs
Economic evidence Unknown The drug has not yet been approved by US 
FDA or European agencies
Abbreviations: LDL, low-density lipoprotein; LFT, liver function test; FDA, Food and Drug Administration.
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as addon therapy to statins or as monotherapy. The most 
potent combination is probably high-dose statins combined 
with ezetimibe and bile acid sequestrants.15 However, even 
if combination therapy is performed at maximal doses, LDL 
cholesterol reduction rarely exceeds 60%.
Another option to decrease LDL cholesterol is regular 
apheresis or plasmapheresis. This treatment modality has been 
in use for more than 30 years.16,17 A single apheresis   usually 
decreases LDL cholesterol by approximately 70%, resulting 
in a mean LDL cholesterol reduction of   approximately 30%. 
However, if regular apheresis is performed at weekly intervals, 
LDL cholesterol does not rebound to the original baseline 
value, resulting in an average LDL   cholesterol concentration 
of approximately 50% of the original baseline value. Several 
studies indicate that FH patients treated with regular apheresis 
benefit from such   treatment.16   Recommendations concerning 
when to initiate such treatment differ considerably between 
countries. In Japan and Germany, where regular apheresis 
is relatively widely used, patients with established coronary 
heart   disease and LDL cholesterol above goal may qualify 
for such treatment. In the US, apheresis is only recommended 
in patients with FH and LDL cholesterol . 300 mg/dL 
(without coronary heart disease) or .200 mg/dL (with 
coronary heart disease).18 Although regular apheresis is a 
time-consuming and cost-intensive form of therapy, it is 
generally well tolerated with very few side effects. Finally, 
liver transplantation can be used in selected cases of 
homozygous FH. This treatment option has been primarily 
used in pediatric patients sometimes as a combined heart-
liver transplant.19
New therapeutic strategies
A number of new therapeutic strategies (Table 1) to lower 
LDL cholesterol have been developed over recent years.20 
These include inhibition of apolipoprotein B production, 
inhibition of PCSK9 production, monoclonal antibodies 
binding to PCSK9, thyroid mimetics, cholesterylester transfer 
protein (CETP) inhibitors, and microsomal triglyceride trans-
fer protein (MTP) inhibitors. All of these approaches have 
been shown to reduce LDL cholesterol to varying degrees. 
Although this review primarily focuses on mipomersen, an 
antisense oligonucleotide for inhibition of production of 
apoprotein B, the other new approaches will also be briefly 
discussed.
Strategies to lower PCSK9
PCSK9 is an important regulator of LDL receptor degrada-
tion, because binding of PCSK9 to the LDL receptor results 
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in degradation of the receptor, thereby preventing recycling 
of the receptor. Loss of function mutations of PCSK9 are 
associated with increased LDL receptor function, low LDL 
cholesterol, and reduced cardiovascular risk.7 PCSK9   activity 
can be reduced by antisense oligonucleotides inhibiting 
PCSK9 production, by small interfering RNAs also inhibiting 
production, or by monoclonal antibodies.21–23 Interestingly, 
statins and fibrates increase PCSK9 expression, probably 
as part of a feedback mechanism following increased LDL 
receptor-mediated uptake of cholesterol during therapy with 
these drugs; therefore, combination therapy may be of par-
ticular potential to reduce LDL cholesterol levels.24 However, 
it should be noted that this approach will only work if func-
tional LDL receptors are present, thus only in heterozygous 
FH and not in the homozygous form of the disease.
Thyroid mimetics
It is well known that hyperthyroidism is associated with low 
LDL cholesterol concentration, and hypothyroidism with 
hypercholesterolemia. A number of selective agonists to the 
thyroid receptor expressed in the liver have been developed. 
One of them, eprotirome, has been shown to decrease LDL cho-
lesterol by approximately 30% if added to a statin.25 However, 
the development of eprotirome was recently stopped because 
of side effects in cartilage seen in animal studies. Whether this 
holds true for the other thyroid mimetics remains unclear.
CETP inhibitors
CETP is a key enzyme of lipid metabolism, and facilitates the 
transfer of cholesterol esters from high-density lipoprotein 
(HDL) particles to other lipoproteins.26 The inhibition 
of CETP results in an increase of HDL cholesterol and 
LDL cholesterol is decreased if torcetrapib, anacetrapib 
or evacetrapib are used, while dalcetrapib has no effect on 
LDL cholesterol levels. The development of torcetrapib has 
been stopped because of off-target effects (blood pressure 
increase) resulting in an unexpected increased mortality and 
morbidity, while the development of Dalcetrapib was stopped 
because of lack of efficacy. Anacetrapib is evaluated in a 
large outcome trial. If these outcome trials show benefit, then 
CETP inhibition may also be useful in patients with FH.
MTP inhibition
MTP  is  an  enzyme  necessary  for  the  assembly  of 
very-low-density lipoprotein. Mutations of MTP result in 
hypobetalipoproteinemia, so MTP inhibition was developed 
as a strategy to lower LDL cholesterol concentrations.27 
MTP inhibition by lomitapide results in an LDL cholesterol 
reduction of approximately 30%. MTP inhibition also induces 
an increase in hepatic steatosis, the importance of which 
is unclear. However, it should be noted that patients with 
hypobetalipoproteinemia also have hepatic steatosis and are 
still characterized by longevity.
Mipomersen: antisense-
oligonucleotide inhibiting 
apolipoprotein B
Apolipoprotein B is the central protein of very-low-density 
lipoprotein, intermediate density lipoprotein, and LDL. 
Although epidemiological and interventional studies have 
focused on LDL-cholesterol, newer data indicate that 
apolipoprotein B concentrations may be a better predictor and 
target for atherosclerosis prevention.28 This also relates to the 
fact that apolipoprotein B containing lipoproteins only contain 
one molecule of apolipoprotein B, while the amount of choles-
terol and cholesterol ester is to a certain point variable (leading 
to LDL size heterogeneity).   Apolipoprotein B is essential for 
the production and catabolism of very-low-density lipoprotein 
and LDL. Without apolipoprotein B, these lipoproteins cannot 
be produced. Furthermore, apolipoprotein B100 is the main 
ligand for the LDL receptor.
Based on these observations, apolipoprotein B is an 
interesting target for atherosclerosis prevention. While 
most currently available approaches (statins, ezetimibe, bile 
acid sequestrants) primarily induce increased catabolism of 
apolipoprotein B-containing lipoproteins, another promis-
ing strategy would be to reduce the production of these 
  lipoproteins. While MTP inhibition also interferes with 
the assembly and secretion of apolipoprotein B-containing 
lipoproteins, a much more direct approach is to reduce the 
production of apolipoprotein B100.
Mipomersen (previously ISIS-301012) is a 20-nucleotide 
second-generation antisense oligonucleotide targeting human 
apolipoprotein B100 that is complementary to a sequence 
within the coding region of human apolipoprotein B mRNA 
(exon 22, position 3249–3269 base pairs).29 Following the bind-
ing of the oligonucleotide to the mRNA, degradation by endog-
enous RNase H is induced. As a consequence, the synthesis of 
apolipoprotein B is reduced, resulting in decreased production 
and secretion of apolipoprotein B-containing lipoproteins. Pro-
duction and secretion of apolipoprotein B48 from enterocytes, 
which is required to form chylomicrons, is not inhibited.
Phase I studies
The initial Phase I study was conducted as a double-blind, 
randomized, placebo-controlled, dose-escalation study in 
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Table 2 Dose-dependent effect of mipomersen on LDL-C, apolipoprotein B, and lipoprotein(a) in Phase II studies of 5–13 weeks’ 
duration (% change compared with baseline)
Subjects Statins n Duration 30 mg/w 50 mg/w 100 mg/w 200 mg/w 300 mg/w 400 mg/w
Heterozygous FH Yes 44 6 w
  LDL-C -13 ± 15 -11 ± 10 -21 ± 23 -34 ± 18
  ApoB -10 ± 12 -8 ± 11 -23 ± 19 -33 ± 22
  Lp(a) -3 ± 10 -15 ± 10 -17 ± 19 -24 ± 26
Hypercholesterolemia Yes 74 5–13 w
  LDL-C 2 ± 12 -21 ± 10 -27 ± 21 -52 ± 14 -38 ± 31
  ApoB 0 ± 12 -19 ± 11 -24 ± 20 -54 ± 19 -44 ± 22
Mild to moderate  
hyperlipidemia
No 50 13 w
  LDL-C -8 -16 -44 -61 -70
  ApoB -17 -22 -45 -61 -71
Abbreviations: ApoB, apolipoprotein B; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); w, week.
36 volunteers with mild dyslipidemia.30 Subjects were treated 
with weekly doses of mipomersen 50–400 mg   subcutaneously. 
Apolipoprotein B and LDL cholesterol were reduced by up 
to 50% and 35%, respectively. No significant changes in 
HDL cholesterol were observed. Apolipoprotein B and LDL 
cholesterol remained below baseline for up to 3 months after 
the last dose. The most common adverse event was erythema 
at the injection site in more than 70% of subjects.
In a second Phase I study, the interaction of mipomersen 
with simvastatin and ezetimibe was evaluated.31 This study 
confirmed that there are no clinically relevant interactions 
between these drugs in 10 healthy volunteers. In addition, 
it was shown that mipomersen does not inhibit the major 
cytochrome P450 isoform enzymes, which is consistent with 
the fact that antisense drugs are not metabolized through the 
cytochrome system.
Phase II studies
In a number of Phase II trials, mipomersen has been 
shown to result in prolonged, dose-dependent reduction 
of LDL   cholesterol, apolipoprotein B, triglycerides, and 
lipoprotein(a), as shown in Table 2. In one study, 44 patients 
with heterozygous FH were enrolled and received doses 
ranging from 50 mg to 300 mg of mipomersen for up to 
13 weeks.32 LDL cholesterol was reduced by 21% in the 
200 mg/week group and 34% in the 300 mg/week group, with 
a reduction in apolipoprotein B of 23% and 33%, respectively. 
Given that all patients were on conventional lipid-lowering 
therapy (statins), this study shows that mipomersen has an 
incremental LDL cholesterol-lowering effect when added to 
conventional lipid-lowering therapy in FH patients.
Similarly, it was shown in a group of 74 patients with 
hypercholesterolemia receiving stable statin therapy that 
mipomersen induced significant changes from baseline in 
apolipoprotein B and LDL cholesterol at doses between 
100 mg and 400 mg per week over 13 weeks, while 30 mg 
per week had no significant effect.33 After 13 weeks of dos-
ing at 200 mg/week, mipomersen reduced apolipoprotein B 
and LDL cholesterol by 36% and triglycerides by 15%. HDL 
cholesterol did not change. Injection site reactions (erythema 
in 90%) and hepatic transaminase increases (17%) were the 
most common side effects, leading to discontinuation in 
three subjects.
The same authors also reported the effect of mipom-
ersen in 50 subjects with mild to moderate hyperlipidemia, 
and showed that doses ranging from 50 mg/week to 
400 mg/week resulted in a dose-dependent reduction in all 
apolipoprotein B-containing lipoproteins over a period of 
13 weeks.34 In the 200 mg/week and 300 mg/week groups, 
mean reductions from baseline in LDL cholesterol were 
45% and 61%, corresponding to a decrease in apolipoprotein 
B concentration of 46% and 61%, respectively. All subjects 
treated with mipomersen experienced injection site reac-
tions and 18% showed transaminase elevations more than 
three times the upper limit of normal. To evaluate further 
the increase in liver function tests, intrahepatic triglyceride 
content was studied by model reference technology in a 
randomized, double-blind, placebo-controlled study in 21 
patients with FH receiving weekly mipomersen doses of 
200 mg or placebo for 13 weeks while continuing statin 
therapy. Mipomersen reduced LDL cholesterol and apoli-
poprotein B by approximately 20%. For the whole group, 
there was a trend towards an increase in intrahepatic trig-
lyceride content, and one patient developed mild hepatic 
steatosis, which was reversible following discontinuation 
of mipomersen.
Phase III studies
Five randomized, double-blind, placebo-controlled Phase 
III studies using 200 mg of mipomersen have been 
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completed.35–39 Only one study is been published in full so 
far, and the others are only available in abstract form. In all 
Phase III studies, mipomersen 200 mg/week was evaluated 
in patients with homozygous FH or heterozygous FH and 
with severe hypercholesterolemia, and in patients with statin 
intolerance. Except for the latter group, mipomersen was 
always coadministered with other lipid-lowering agents, 
including statins. The duration of all the Phase III studies was 
26 weeks, and the primary and secondary efficacy endpoints 
were met in all cases (Table 3).
Mipomersen 200 mg/week was tested in a multicenter 
study of 51 patients with homozygous FH on a low-fat diet 
and maximum tolerated lipid-lowering drugs. Thirty-four 
patients were assigned to mipomersen and 17 to placebo. 
LDL cholesterol (mean at baseline 11.4 ± 3.6 mmol/L) 
decreased by 24.7%. Similarly, apolipoprotein B decreased 
by 26.8% and lipoprotein(a) by 31.1%. In line with the 
Phase II studies, the most common adverse events were 
injection site reactions (76% in the mipomersen group and 
24% in the placebo group) and increases in liver function 
tests (12% in the mipomersen group).36
In 124 adult patients with heterozygous FH and cardio-
vascular disease, 26 weeks of mipomersen 200 mg/week 
resulted in an LDL cholesterol reduction of 34%, an 
apolipoprotein B reduction of 26.3%, and a lipoprotein(a) 
reduction of 20%. Again, injection site reactions and flu-
like symptoms were the most common adverse events. 
Liver function tests increased to more than three times 
the upper limit of normal in 6% of patients treated with 
mipomersen.37
Another study evaluated mipomersen in 58 patients with 
severe FH. Mipomersen 200 mg/week for 26 weeks reduced 
LDL cholesterol by 36% from a mean baseline level of 
276 mg/dL and also significantly decreased apolipoprotein B 
and lipoprotein(a), with no change in HDL cholesterol. 
Side effects were similar as in other mipomersen studies, 
with injection site reactions (90% in mipomersen group, 
32% in placebo group) and flu-like symptoms (46% in 
mipomersen group, 21% in placebo group) being the most 
common adverse events. In 15% of mipomersen-treated 
patients (but in none of the placebo patients) alanine 
  aminotransferase was elevated to above three times the 
upper limit of normal.38
In a larger study in 158 adults with hypercholester-
olemia and high cardiovascular risk, mipomersen 200 mg/
week for 26 weeks reduced LDL cholesterol by 37%, with 
similar changes in apolipoprotein B and lipoprotein(a). 
In 50% of mipomersen-treated patients, LDL cholesterol 
was decreased to ,70 mg/dL. Injection site reactions and 
flu-like symptoms were again the most common side effect. 
Fourteen percent of mipomersen-treated patients had alanine 
aminotransferase elevations above three times the upper 
limit of normal.35
Finally, mipomersen 200 mg/week for 26 weeks was 
evaluated in high-risk patients intolerant to statins.39 LDL 
cholesterol decreased by 47.3%, with a similar decrease in 
apolipoprotein B (46.2%) and a decrease of lipoprotein(a) 
by 27.1%. Eighteen percent of the mipomersen-treated 
patients and 17% of the placebo-treated patients discon-
tinued due to adverse events. As in statin-tolerant patients, 
injection site reactions and flu-like symptoms were the most 
common side effects. Liver function tests were above three 
times the upper limit of normal in 33% of mipomersen-
treated patients.
Efficacy of mipomersen
Mipomersen results in a dose-dependent reduction of 
LDL cholesterol, lipoprotein(a), apolipoprotein B100, and 
triglycerides. At the dose chosen for further development 
(200 mg/week), LDL cholesterol reduction varies between 
30% and 47% compared with placebo. Apolipoprotein B 
and lipoprotein(a) reduction is slightly less at 20%–35%. 
Triglyceride reduction is more variable and usually 
between 10% and 20%. Within each study, there is con-
siderable variability in the reduction of LDL cholesterol, 
for example, in homozygous FH, LDL reduction varied 
between 2% and 82%. If reported, the treatment effect was 
independent of baseline LDL cholesterol values, age, race, 
or gender. The observed reduction in LDL cholesterol, 
lipoprotein(a), and apolipoprotein B seems to be indepen-
dent of the underlying cause and independent of concomitant 
drug therapy.
Safety and tolerability
Mipomersen has been generally well tolerated and had 
an acceptable safety profile in the Phase II and Phase III 
  studies. The most common adverse events were injection site 
reactions, flu-like symptoms, and increases in liver function 
tests, especially alanine aminotransferase.
Injection site reactions occur in most patients (75%–100%). 
These are dose-dependent and characterized by transient, 
mild to moderate erythema, occurring within 24 hours of 
drug injection. On subsequent injection, a flare-up of the 
previous injection site may occur. Injection site reactions 
are considered an antisense class-related phenomenon also 
observed with other antisense drugs. However, the exact 
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underlying mechanism is unknown. Injection site reactions 
are not considered to be serious safety concerns but may 
affect patient compliance.
Flu-like symptoms were reported somewhat more often 
in the mipomersen groups than in the placebo groups. 
Elevated transaminases (alanine aminotransferase level more 
than three times the upper limit of normal) was observed in 
6%–15% of mipomersen-treated patients (0% in the placebo 
groups). These elevations were not accompanied by other 
clinical or laboratory findings suggestive of hepatic dysfunc-
tion nor were there any cases of Hy’s law. Elevated alanine 
aminotransferase most likely reflects accumulation of hepatic 
fat secondary to inhibition of apolipoprotein B synthesis and 
therefore very-low-density lipoprotein secretion. Hepatic 
steatosis has been observed in some mipomersen-treated 
patients.40 Hepatic steatosis resolves and alanine aminotrans-
ferase elevations return to normal after discontinuation of 
treatment.
Therapeutic potential  
of mipomersen
The currently available studies indicate that mipomersen may 
decrease LDL cholesterol in homozygous and heterozygous 
FH patients by approximately 30%, independent of concomi-
tant drug therapy. The effect of mipomersen in patients treated 
with apheresis is currently unknown, but there is little doubt 
about similar efficacy in such patients.
Thus, mipomersen could theoretically be used in all 
patients not at goal with respect to LDL cholesterol and at 
sufficient absolute risk to justify treatment with a drug for 
which no long-term data are currently available. Mipomersen 
may be of particular benefit to patients with homozygous FH 
or severe heterozygous FH, given that treatment options are 
very limited in such patients. It should also be noted that 
mipomersen, in contrast with other established approaches, 
such as statins, bile acid-binding resins, and ezetimibe, and 
in contrast with other newly developed approaches, such 
as PCSK9 inhibitors, does not rely on the LDL receptor to 
achieve LDL cholesterol reduction.
The following patient groups may be primary candidates 
for treatment with mipomersen:
•	 Patients with homozygous FH, many of whom do not 
respond to statin therapy and even if they do, usually 
do not reach treatment goals. In this patient group, 
a Phase III study has shown efficacy with respect to LDL, 
apolipoprotein B, and lipoprotein(a) reduction.
•	 Patients with severe heterozygous FH, who usually 
respond to statin therapy, with an LDL cholesterol 
reduction of up to 50%, but may not reach treatment goals 
either because baseline values are too high or because 
they do not tolerate high-dose statins. Mipomersen as 
an addon therapy to a statin (and potentially ezetimibe 
and bile-acid binding resins) may further reduce LDL 
cholesterol and result in a considerably larger fraction 
of patients reaching treatment goals. Such patients have 
been studied in a Phase III trial, but the results have only 
been published in abstract form so far.
•	 Patients with severe hypercholesterolemia and coronary 
heart disease not reaching treatment goals. Similar to 
patients with heterozygous FH, these patients usually 
respond to conventional drug therapy, but efficacy may be 
inadequate. Addon therapy with mipomersen may allow 
more patients to reach treatment goals.
•	 Patients at high risk for atherosclerosis intolerant to 
statin therapy, in whom mipomersen may be a treatment 
alternative allowing attainment of treatment goals.
Theoretically, all patients qualifying for regular   apheresis 
should be candidates for mipomersen treatment. In fact, 
according to German guidelines, a hypothetical evaluation 
shows that approximately 50% of aphereses could be avoided 
if mipomersen was available on the German market and toler-
ated as well as apheresis.41 Obviously, mipomersen may also 
be an interesting addon therapy to apheresis, which may lead 
to lower pre-apheresis and post-apheresis values, and thus 
to better average values. In some patients, this may have the 
benefit of apheresis being required less frequently. However, 
before mipomersen can be used as concomitant therapy in 
apheresis-treated patients, a proper study must be performed 
in this patient group.
Although mipomersen has a significant ability to 
lower LDL, apolipoprotein B, and lipoprotein(a), and 
may thus allow more people to reach therapeutic goals, it 
also has significant side effects (injection site reactions, 
elevation of transaminases) which may affect compliance 
and must be taken into account in cost-benefit analysis. Until 
more long-term data are available, especially with respect to 
elevated liver enzymes, this form of therapy will be used pri-
marily in patients with severe forms of hypercholesterolemia 
and at very high cardiovascular risk.
In summary, inhibition of apolipoprotein B production 
using mipomersen may be an interesting approach for patients 
with heterozygous and homozygous FH not at target with 
current forms of drug therapy. Mipomersen reduces LDL 
cholesterol by up to 45%, but leads to injection site reactions 
in almost all patients, and flu-like symptoms and elevated 
transaminases in some.
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